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Abstract
Background: The aim of our study was to investigate the influence of conventional synthetic disease-modifying
anti-rheumatic drugs (csDMARDs) and body mass index (BMI) on circulating drug levels and clinical response to
tumour necrosis factor inhibitor (TNFi) therapy in axial spondyloarthritis (axSpA) patients.
Methods: Prospective observational study during 1 year with 2 cohorts (Madrid and Amsterdam) including 180
axSpA patients treated with standard doses of infliximab or adalimumab. Patients were stratified by BMI, being
78 (43%) normal weight (18.5–24.9 kg/m2) and 102 (57%) overweight/obese (≥ 25.0 kg/m2). After the first year
of treatment, TNFi trough levels were measured by capture ELISA. Clinical response to TNFi was defined as
ΔBASDAI ≥ 2 and clinical remission as BASDAI < 2 and CRP ≤ 5 mg/L. Logistic regression models were employed to
analyse the association between concomitant csDMARDs and BMI with drug levels and clinical response.
Results: Seventy-nine patients (44%) received concomitant csDMARDs. The administration of concomitant
csDMARDs (OR 3.82; 95% CI 1.06–13.84) and being normal weight (OR 18.38; 95% CI 2.24–150.63) were independently
associated with serum TNFi drug persistence. Additionally, the use of concomitant csDMARDs contributed positively to
achieve clinical response (OR 7.86; 95% CI 2.39–25.78) and remission (OR 4.84; 95% CI 1.09–21.36) in overweight/obese
patients, but no association was found for normal-weight patients (OR 1.10; 0.33–3.58).
Conclusions: The use of concomitant csDMARDs with TNFi may increase the probability of achieving clinical response
in overweight/obese axSpA patients. Further research studies including larger cohorts of patients need to be done to
confirm it.
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Introduction
In patients suffering from spondyloarthritis (SpA), conven-
tional synthetic disease-modifying anti-rheumatic drugs
(csDMARDs), such as methotrexate (MTX) and sulfasala-
zine (SSZ), can be useful for treating peripheral joint mani-
festations. However, they have not shown to be efficient for
axial manifestations and therefore are not recommended
by ASAS-EULAR to control axial disease [1].
Nevertheless, it has been described that the phe-
nomenon of immunogenicity, an immune response that
may hamper the efficacy of TNF inhibitor (TNFi)
monoclonal antibodies [2, 3], can be modulated by
co-administration of csDMARDs. To this regard, con-
comitant use of certain csDMARDs, especially MTX,
may ameliorate the immunogenicity of infliximab and
adalimumab by reducing anti-drug antibody (ADA)
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formation and therefore maintaining serum drug circu-
lating levels and prolonging drug survival [4, 5].
However, immunogenicity is not the only cause for losing
response to TNFi therapy. Other factors may be of influ-
ence. Currently, obesity is being considered as a risk factor
for worsening clinical parameters of disease activity in pa-
tients with ankylosing spondylitis (AS). The increase of
pro-inflammatory adipokines during obesity, such as vinfas-
tin, correlates with the progression of radiographic damage
in AS [6]. Furthermore, an increased body mass index
(BMI) has been recently found to be associated with signifi-
cantly lower response rates to TNFi in patients with axial
(axSpA) [7, 8]. Some studies have furthermore demon-
strated that high BMI is negatively associated with TNFi
serum drug levels [9, 10].
In summary, both BMI and csDMARDs are associated
with serum TNFi level persistence, but only BMI seems to
be associated on clinical response to this therapy. To extent
the knowledge on the relationship of these factors, the aim
of this study was to investigate the influence of both BMI
and concomitant csDMARDs on serum TNFi persistence as
well as on the clinical response in patients with axSpA [7, 8].
Methods
Study design and patients
This was a prospective observational study. Data from two
different cohorts including patients diagnosed of axSpA
treated with standard doses of infliximab or adalimumab
(infliximab 5mg/kg at 0, 2, 6 weeks and later every 8 weeks;
adalimumab 40mg/2 weeks) according to the clinical prac-
tice guidelines were analysed. No modifications in the dose
or interval of administration were carried out. Patients
were included from June 2000 to June 2015. All included
patients were diagnosed as axSpA according to physician
criteria. The adherence to ASAS criteria was verified before
including them into the study [11, 12]. When the datasets
were locked (November 2016), a total of 246 patients had
been enrolled in these cohorts: 166 from a Spanish incep-
tion cohort at the Department of Rheumatology of La Paz
University Hospital (Madrid) and 80 from a Netherland co-
hort at the Department of Rheumatology of Reade Center
(Amsterdam). For this study, only patients who had base-
line BMI data available and serum drug levels measured or
disease activity assessment during the first year of TNFi
therapy after 1 year of starting infliximab or adalimumab
were selected (n = 180). Out of these, 81% were naïve to
biological therapy. It was described in a flowchart in
Additional file 1. Non-radiographic axSpA and radio-
graphic axSpA were defined according to physician and
clinical practice, but imaging was not systematically read
for this study. The study was conducted according to the
guidelines of the 1975 Declaration of Helsinki. Approval
was obtained from the Institutional Ethics Committee
from both centres.
Clinical disease activity assessment
Disease activity was assessed by Bath Ankylosing Spon-
dylitis Disease Activity Index (BASDAI) and Ankylosing
Spondylitis Disease Activity Score (ASDAS) at baseline
(before starting TNFi treatment) and after 1 year of
treatment. Clinical response to TNFi was defined as
ΔBASDAI ≥ 2 and as ΔASDAS ≥ 1.1. Clinical remission
was defined as BASDAI < 2 and CRP ≤ 5 mg/L and as
ASDAS < 1.3. For all analyses, BASDAI was considered as
the main variable due to the later development of the
ASDAS in 2010, which explained why fewer patients from
both cohorts were evaluated by this score (n = 170 patients
with BASDAI score and n = 141 patients with ASDAS).
Determination of drug levels and anti-drug antibodies
Blood samples were collected at 24 h maximum before
drug administration for adalimumab or immediately be-
fore intravenous infusions for infliximab.
Serum drug concentrations were determined by a cap-
ture enzyme-linked immunosorbent assay (ELISA), as de-
scribed previously [13], using specific biotin-conjugated
anti-idiotype antibodies to infliximab and adalimumab.
Threshold values for positive drug levels were 10 ng/mL
for infliximab and 5 ng/mL for adalimumab.
Serum anti-drug antibody (ADA) levels were analysed
by radioimmunoassay (RIA), as described previously [14],
using 125I-infliximab F(ab’)2 or
125I-adalimumab F(ab’)2.
Threshold values for positive ADA levels were 12 AU/mL.
Statistical analyses
First, descriptive analysis was employed. According to BMI,
patients were classified as normal weight (18.5–24.9 kg/m2)
and overweight/obese (≥ 25.0 kg/m2). Differences between
the groups were assessed using the unpaired t test or
Mann-Whitney U test for continuous variables depending
on the distribution and Fisher’s exact test for ordinal
variables. Second, the association between concomitant
csDMARDs and BMI with drug persistence and clinical
response to TNFi at 1 year was analysed through univari-
ate and multivariate logistic regression models. Interac-
tions with age, gender, HLA-B27, BMI, csDMARDs and
symptom duration were tested. If relevant interactions
were found, analyses were stratified. If not, variables were
entered as covariates. Additionally, the type of TNFi for
drug persistence outcome and baseline disease activity
(BASDAI and CRP) for clinical response outcome were in-
cluded as covariates. Results are shown as odds ratio (OR)
and 95% confidence interval (CI).
For TNFi levels, the last observation carried forward
method (LOCF) was performed to include patients who
dropped out before 1 year of follow-up (n = 43). Statistical
significance was calculated considering p value < 0.05 sta-
tistically significant. The Statistical Package for the Social
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From a total of 246 patients, 180 patients with axSpA
starting infliximab (n = 74) or adalimumab (n = 106)
were included in the study. Patient and disease charac-
teristics at baseline are shown in Table 1. There were no
differences between the total group of patients and the
patients included in the study. A total of 79 (44%) pa-
tients received concomitant csDMARD distributed as
follows: MTX (25; 14%), SSZ (36; 20%) and MTX+SSZ
(18; 10%). According to BMI, 78 (43%) patients were
normal weight (18.5–24.9 kg/m2) and 102 (57%) were
overweight/obese (≥ 25.0 kg/m2). Overall, no differ-
ences between both groups of BMI were found, except
for age, sex, disease duration, TNFi type and concomi-
tant sulfasalazine.
Effect of concomitant csDMARDs and BMI on persistence
of TNFi in serum
A total of 157 patients (87%) had detectable circulating
TNFi levels after 1 year of treatment. For this outcome,
no significant interaction with other variables was found.
Univariable analyses were performed to analyse the asso-
ciation between the persistence of serum TNFi and each
variable included in Table 1. A significant association
was found for being male (OR 0.32; 95% CI 0.11–0.89),
disease duration (OR 0.94; 95% CI 0.90–0.98), being nor-
mal weight (OR 9.85; 95% CI 2.23–43.44) and concomi-
tant csDMARDs (OR 2.71; 95% CI 1.03–7.14). In the
multivariable logistic regression model, disease duration
(OR 0.93; 95% CI 0.88–0.99), concomitant csDMARDs
(OR 3.82; 95% CI 1.06–13.84) and especially being normal
weight (OR 18.38; 95% CI 2.24–150.63) remained independ-
ently associated with serum TNFi persistence after 1 year
of treatment (Table 2). Specifically, all the patients con-
comitantly treated with MTX [± SSZ] showed detectable






BMI ≤ 25 (n = 78)
Included patients
BMI > 25 (n = 102)
Age (years) 47.6 ± 13.1 47.0 ± 12.7 42.9 ± 11.7 50.1 ± 12.6***
Male 146 (59) 107 (59) 39 (50) 68 (67)*
Disease duration (years) 10 (5–16) 8 (5–16) 7 (3–13) 9 (6–18)**
SpA subtype
Ankylosing spondylitis 179 (78) 140 (78) 64 (82) 76 (74)
Non-radiographic SpA 49 (22) 40 (22) 14 (18) 26 (26)
HLA-B27 174 (74) 131 (73) 61 (78) 70 (69)
Psoriasis/IBD/uveitis 71 (29) 58 (32) 27 (35) 31 (30)
Peripheral arthritis 97 (40) 86 (48) 38 (49) 48 (47)
BASDAI 5.8 ± 2.0 5.8 ± 2.0 5.5 ± 2.1 6.0 ± 1.9
ASDAS 3.3 ± 0.9 3.3 ± 1.0 3.2 ± 1.0 3.4 ± 1.0
ESR (mmHg) 17 (7–33) 17 (7–31) 19 (6–34) 16 (7–31)
CRP (mg/L) 5 (2–15) 6 (3–17) 7 (2–20) 5 (3–15)
Previous TNFi 43 (18) 35 (19) 13 (17) 22 (21)
TNFi type
Infliximab 107 (43) 74 (41) 25 (32) 49 (48)*
Adalimumab 139 (57) 106 (59) 53 (68) 53 (52)*
csDMARD
Any csDMARD 102 (42) 79 (44) 31 (40) 48 (47)
MTX 34 (15) 25 (14) 12 (15) 13 (13)
SSZ 46 (21) 36 (20) 10 (13) 26 (25)*
MTX and SSZ 22 (9) 18 (10) 9 (11) 9 (9)
Prednisone 22 (9) 20 (11) 11 (14) 9 (9)
The table shows mean ± SD, median (IQR) or absolute number (percentage) for all patients included (n = 180). The results are also stratified by body mass index
(BMI). p value < 0.05 was considered statistically significant. Significant statistical differences between the groups of included patients, stratified by BMI: *p < 0.05,
**p < 0.01, ***p < 0.001. SpA spondyloarthritis, HLA-B27 human leucocyte antigen B27, ESR erythrocyte sedimentation rate, CRP C-reactive protein, IBD inflammatory
bowel disease, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ASDAS Ankylosing Spondylitis Disease Activity Index, TNFi tumour necrosis factor
inhibitors, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, MTX methotrexate, SSZ sulfasalazine
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TNFi levels after 1 year of treatment. At the same time,
lower percentages of patients showing detectable TNFi
levels after 1 year of treatment were found in the groups
under TNFi monotherapy (83/101; 82%) or concomitantly
treated with SSZ alone (31/36; 86%).
These results were similar, regardless of the TNFi type.
Patients receiving TNFi as monotherapy showed a
higher percentage of undetectable drug levels than pa-
tients treated with MTX [± SSZ] after 1 year of treat-
ment, regardless of the TNFi type (28% for infliximab,
17% for adalimumab; p = 0.2).
Concerning the association with BMI, patients who
showed undetectable TNFi presented mainly overweight/
obese (n = 21/23; 91%), regardless of the TNFi type.
Effect of concomitant csDMARDs and BMI on ADA
development
Thirty-eight out of 180 patients (21%) developed ADA at
1 year of TNFi treatment. The development of ADA for
each therapeutic group was as follows: 30/101 (30%) pa-
tients under TNFi monotherapy, 7/36 (19%) patients
treated with SSZ (p = 1.0) and 1/43 (2%) patients treated
with MTX [± SSZ] (p = 0.03). The provided p values were
obtained by comparison with TNFi monotherapy. ADA
development was significantly negatively associated with
TNFi persistence (β − 3.94; OR 0.02; 95% CI 0.005–0.72).
Moreover, a higher BMI was associated with the devel-
opment of ADA (p = 0.002). Forty-five percent of obese
patients (15/35) were ADA positive at 1 year of treatment.
On the other hand, ADA development was lower in over-
weight (11/69; 16%) as well as normal-weight (12/78; 15%)
patients. No statistical differences were observed between
the overweight and normal-weight groups.
Effect of concomitant csDMARDs and BMI on clinical
outcomes
Effect on clinical response
Patients had active disease at baseline, as indicated by a
mean BASDAI of 5.8 and a mean ASDAS of 3.3. After 1
year of TNFi treatment, 48% (n = 68) of the patients
achieved BASDAI clinical response. For this outcome, a
relevant interaction between csDMARDs and BMI with
clinical response was found (Wald chi-square value 3.63;
p = 0.057), and therefore, the results were stratified ac-
cording to BMI. The results showed that the use of con-
comitant csDMARDs contributed positively to achieve
BASDAI clinical response in overweight/obese patients
(OR 7.86; 95% CI 2.39–25.78); however, no association
was found for normal-weight patients (OR 1.10; 95% CI
0.33–3.58) (Table 3).
Furthermore, the influence of csDMARD type on these
associations was also investigated. Concomitant MTX
[± SSZ] (OR 9.82; 95% CI 2.13–45.20) as well as
concomitant SSZ alone (OR 6.86; 95% CI 1.85–25.40)
contributed to achieve BASDAI clinical response in
overweight/obese patients.
Effect on clinical remission
After 1 year of treatment with TNFi, 25% (n = 35) of pa-
tients achieved clinical remission. Similarly to the results
observed for clinical response, the analysis revealed that
the use of csDMARDs contributes to achieve BASDAI
clinical remission in overweight/obese patients (OR 4.84;
95% CI 1.09–21.36) (Table 3). The individual results for
csDMARD type were analysed, but neither concomitant
MTX [± SSZ] (OR 5.56; 95% CI 0.84–36.52) nor concomi-
tant SSZ (OR 4.35; 0.77–24.54) showed significant results.
Sensitivity analyses
Finally, sensitivity analyses were performed employing
ASDAS definition for clinical response using data from 119
Table 2 Association between csDMARDs and BMI with the




Disease duration 0.93 0.88–0.99*
TNFi type (ref: infliximab) 0.46 0.15–1.39
csDMARD (ref: use of any csDMARD) 3.82 1.06–13.84*
BMI (ref: normal weight) 18.38 2.24–150.63*
The adjusted multivariable logistic regression analysis included 161 patients.
Odds ratio (OR) and 95% confidence interval (CI) were calculated. *p value < 0.05
was considered statistically significant. TNFi tumour necrosis factor inhibitors,
csDMARD conventional synthetic disease-modifying anti-rheumatic drug, BMI
body mass index
Table 3 Association between csDMARDs and clinical response
(ΔBASDAI ≥ 2.0) or remission (BASDAI < 2 and CRP ≤ 5 mg/L) at
1 year, stratified for body mass index
BMI ≤ 25 (n = 60; 42%) BMI > 25 (n = 81; 58%)
OR 95% CI OR 95% CI
Clinical response
Any csDMARD 1.10 0.33–3.58 7.86 2.39–25.78*
MTX [± SSZ] 1.04 0.25–4.25 9.82 2.13–45.20*
SSZ 1.18 0.25–5.63 6.86 1.85–25.40*
Remission
Any csDMARD 0.76 0.20–2.86 4.84 1.09–21.36*
MTX [± SSZ] 0.60 0.11–3.18 5.56 0.84–36.52
SSZ 0.99 0.17–5.64 4.35 0.77–24.54
The adjusted multivariable logistic regression analysis included 141 patients.
Two different models are presented for the following outcomes: clinical
response and remission. Odds ratio (OR) and 95% confidence interval (CI) were
calculated. All models were adjusted for age, gender, disease duration,
HLA-B27, baseline BASDAI and CRP. *p value < 0.05 was considered statistically
significant. BMI body mass index, HLA-B27 human leucocyte antigen B27, CRP
C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index,
csDMARD conventional synthetic
disease-modifying anti-rheumatic drug, MTX methotrexate, SSZ sulfasalazine
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patients in which ASDAS was available. Out of these, 45%
(n = 53) of patients achieved clinical response and 29% (n =
34) remission. The results found were consistent with the
evaluation with BASDAI, being the probability of achieving
clinical response in overweight/obese patients increased by
the use of concomitant csDMARD (Additional file 1). How-
ever, these results were not statistically significant, due to
the smaller sample size.
Discussion
This study investigates the influence of concomitant
csDMARDs and BMI on circulating drug levels as well
as on the clinical response to TNFi therapy in axSpA pa-
tients. The observed results show that both concomitant
csDMARDs and especially BMI were associated with
TNFi drug persistence. Furthermore, the concomitant
treatment with csDMARDs (MTX and/or SSZ) was also
associated with good clinical response in overweight/
obese axSpA patients receiving TNFi but not in normal-
weight patients.
According to previous data, BMI and csDMARDs were
found to have an influence on TNFi clearance [8]. Particu-
larly, MTX was more effective in reducing immunogenicity.
However, the effect of BMI seems to be more relevant. Dif-
ferent studies have suggested that higher BMI is associated
with a higher volume of distribution in the central compart-
ment and therefore with increased TNFi clearance [7–10].
Up to date, there are no clear data about the clinical
superiority of co-therapy csDMARDs+TNFi vs. TNFi in
monotherapy for the treatment of axSpA [1]. Recently,
Sepriano et al. indicated that co-medication with
csDMARDs do not prolong TNFi retention in axSpA
[15]. To this regard, we observed that the use of concomi-
tant csDMARDs have no influence on the clinical response
for normal-weight patients and therefore support previous
data. However, csDMARDs were associated with a higher
probability of having both BASDAI clinical response and
clinical remission in patients being overweight or obese. An
explanation for this association could be the fact that obes-
ity might be considered as additional inflammation where
pro-inflammatory adipokines, such as TNFα, IL1β, IL6 or
MCP1, are segregated by adipose tissue and macrophages
[16]. Therefore, the concomitant treatment with immuno-
modulators (csDMARDs) would allow decreasing the
production of these adipokines helping to restore inflam-
mation balance [17, 18]. TNFi would achieve the clinical
outcome, once decreased the effect of the overweight/obese
pro-inflammatory environment.
Nevertheless, the results of this study need to be inter-
preted with caution. It is well known that studies testing
treatment effects without blinded and random treatment
allocation are at risk for confounding by indication. In
our study, csDMARD prescription was not randomised
and was done according to the clinical criteria by the
treating physician. Patients who were prescribed
csDMARDs may be inherently different from those who
did not take these drugs, and such differences can drive
the positive association rather than the treatment itself.
So, confounding by indication needs to be considered as
the main limitation of this study. On the other hand, we
are convinced that the reason to prescribe concomitant
csDMARDs were not based on BMI because this is not
the clinical practice in the participant centres.
This study presents other limitations that need to be
kept in mind when interpreting the results: (i) Statistical
analyses could not be adjusted for smoking habit be-
cause it was not registered. (ii) Some patients were
included before 2010, when ASDAS was not available,
and therefore, the sample size for these analyses was re-
duced; the results obtained for this analysis showed a
similar trend to that of BASDAI clinical response but
were not statistically significant. The lower number of
patients with ASDAS registered may be an explanation.
Furthermore, a different explanation could be that
ASDAS was not really influenced by BMI. In this regard,
it has recently been published that it would not be ne-
cessary to take BMI into account when assessing disease
activity by ASDAS in axSpA patients with high BMI
[19]. (iii) LOCF was employed for patients who dropped
out before 1 year of follow-up (n = 43). (iv) csDMARD
prescription was not randomised, although prescription
followed clinical criteria. (v) Patients are included from
two different centres with some differences in the thera-
peutic strategy. (vi) BMI and csDMARD information
was collected only at baseline, and therefore, the possible
change on these over the study period was not taken
into account. (vii) The compliance in adalimumab,
SSZ and MTX administrations could not be ensured
in all patients.
Conclusions
In conclusion, our study suggests that the use of
concomitant csDMARDs with TNFi would not be
justified in axSpA patients with normal weight as it
would not increase the probability of achieving clin-
ical response. Moreover, in agreement with previous
data, it also suggests that BMI is associated with
lower TNFi serum drug persistence. Therefore, obese
patients should be encouraged to achieving normal
weight. Nevertheless, based on the results of this
study, if losing weight is proven impossible, it can be
hypothesised that the co-medication with csDMARDs
(MTX or SSZ) could be of additional value to in-
crease treatment success in overweight/obese patients.
However, before implementing the results of this
study, further research studies with better methodo-
logical design including larger cohorts of patients
need to confirm them.
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Additional file
Additional file 1: (i) Association between csDMARDs and clinical
response (ΔASDAS≥1.1) or remission (ASDAS<1.3) at one year, stratified
for body mass index; (ii) Flowchart of patients included in the present
study. (DOCX 46 kb)
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